PYXS
Pyxis Oncology, Inc.
+0.02 (+0.60%)3.36USD163K成交股數280M市值–本益比(近四季)20.2股價營收比–營收年增(近四季)2026-11-02下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 1 · 107K · 1 |
| 其中 10b5-1 計畫賣出 | 1 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 107K |
| 近 180 天 淨額 | −107K |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 07-02 | Dupont Jakob | Director | S 公開市場賣出(10b5-1) | 35.0K | 3.06 | 107K | 38.7K | SEC |
| 2026-06-30 | 07-02 | Dupont Jakob | Director | M 選擇權執行 | 35.0K | 1.60 | 56K | 73.7K | SEC |
| 2026-03-24 | 03-25 | Wadhane Jitendra | Prin Fin & Acct Officer | A 獲配股票 | 109K | – | – | 513K | SEC |
| 2025-04-21 | 03-25 | HUMPHREY RACHEL | Director | S 公開市場賣出(10b5-1) | 13.9K | 1.03 | 14K | 81.3K | SEC |
| 2025-04-17 | 03-25 | HUMPHREY RACHEL | Director | S 公開市場賣出(10b5-1) | 200 | 0.97 | 194.00 | 95.2K | SEC |
| 2025-04-14 | 03-25 | HUMPHREY RACHEL | Director | S 公開市場賣出(10b5-1) | 1.4K | 0.97 | 1K | 95.4K | SEC |
| 2024-11-26 | 11-27 | Connealy Pamela Ann | CFO & COO | P 公開市場買進 | 5.5K | 2.00 | 11K | 1.1M | SEC |
| 2024-11-26 | 11-27 | Connealy Pamela Ann | CFO & COO | P 公開市場買進 | 83.4K | 1.96 | 163K | 1.2M | SEC |
| 2024-06-07 | 06-07 | Palani Santhosh | Director | A 獲配股票 | 6.0K | – | – | 6.0K | SEC |
| 2024-03-26 | 03-28 | Wadhane Jitendra | SVP, Chief Accounting Officer | A 獲配股票 | 131K | – | – | 398K | SEC |
| 2024-03-26 | 03-28 | HUMPHREY RACHEL | Director | A 獲配股票 | 38.7K | – | – | 96.8K | SEC |
| 2024-03-26 | 03-28 | Dupont Jakob | Director | A 獲配股票 | 38.7K | – | – | 38.7K | SEC |
| 2024-03-26 | 03-28 | Lewis-Hall Freda C | Director | A 獲配股票 | 35.2K | – | – | 241K | SEC |
| 2024-03-26 | 03-28 | FLAVIN JOHN L | Director | A 獲配股票 | 35.2K | – | – | 413K | SEC |
| 2024-03-26 | 03-28 | Cline Darren S | Director | A 獲配股票 | 35.2K | – | – | 251K | SEC |
| 2024-03-26 | 03-28 | Connealy Pamela Ann | CFO & COO | A 獲配股票 | 329K | – | – | 1.1M | SEC |
| 2023-11-29 | 11-30 | Connealy Pamela Ann | CFO and COO | F 繳稅扣股 | 36.9K | 1.40 | 52K | 782K | SEC |
| 2023-11-15 | 11-17 | Wadhane Jitendra | Chief Accounting Officer | A 獲配股票 | 40.0K | – | – | 267K | SEC |
| 2023-09-28 | 09-28 | Connealy Pamela Ann | CFO and COO | P 公開市場買進 | 8.0K | 1.87 | 15K | 819K | SEC |
| 2023-09-27 | 09-27 | Connealy Pamela Ann | CFO and COO | P 公開市場買進 | 6.4K | 1.85 | 12K | 811K | SEC |
| 2023-09-27 | 09-27 | Wadhane Jitendra | Chief Accounting Officer | P 公開市場買進 | 2.5K | 1.87 | 5K | 227K | SEC |
| 2023-09-25 | 09-25 | Connealy Pamela Ann | CFO and COO | P 公開市場買進 | 12.0K | 1.67 | 20K | 804K | SEC |
| 2023-09-25 | 09-25 | Wadhane Jitendra | Chief Accounting Officer | P 公開市場買進 | 5.0K | 1.77 | 9K | 224K | SEC |
| 2023-09-22 | 09-22 | Connealy Pamela Ann | CFO and COO | P 公開市場買進 | 5.0K | 1.74 | 9K | 792K | SEC |
| 2023-09-22 | 09-22 | Wadhane Jitendra | Chief Accounting Officer | P 公開市場買進 | 2.5K | 1.74 | 4K | 219K | SEC |
| 2023-09-18 | 09-18 | Sullivan Lara | President and CEO | S 公開市場賣出 | 8.5K | 2.10 | 18K | 2.4M | SEC |
| 2023-09-14 | 09-18 | Sullivan Lara | President and CEO | S 公開市場賣出 | 100 | 2.25 | 225.00 | 2.4M | SEC |
| 2023-09-13 | 09-13 | Sullivan Lara | President and CEO | F 繳稅扣股 | 185K | 2.13 | 394K | 2.4M | SEC |
| 2023-09-13 | 09-13 | Sullivan Lara | President and CEO | S 公開市場賣出 | 3.0K | 2.27 | 7K | 2.6M | SEC |
| 2023-09-12 | 09-13 | Sullivan Lara | President and CEO | S 公開市場賣出 | 4.9K | 2.25 | 11K | 2.6M | SEC |
| 2023-09-11 | 09-13 | Sullivan Lara | President and CEO | S 公開市場賣出 | 20.0K | 2.27 | 45K | 2.6M | SEC |
| 2023-09-07 | 09-08 | Connealy Pamela Ann | CFO and COO | A 獲配股票 | 188K | – | – | 782K | SEC |
| 2023-09-07 | 09-08 | Sullivan Lara | President and CEO | A 獲配股票 | 469K | – | – | 2.6M | SEC |
| 2023-09-07 | 09-08 | Wadhane Jitendra | Chief Accounting Officer | A 獲配股票 | 93.9K | – | – | 212K | SEC |
| 2023-03-24 | 03-28 | Wadhane Jitendra | Chief Accounting Officer | A 獲配股票 | 29.4K | – | – | 118K | SEC |
| 2023-03-24 | 03-28 | Civik Thomas | Director | A 獲配股票 | 139K | – | – | 206K | SEC |
| 2023-03-24 | 03-28 | Cline Darren S | Director | A 獲配股票 | 139K | – | – | 216K | SEC |
| 2023-03-24 | 03-28 | FLAVIN JOHN L | Director | A 獲配股票 | 139K | – | – | 378K | SEC |
| 2023-03-24 | 03-28 | HUMPHREY RACHEL | Director | A 獲配股票 | 58.1K | – | – | 58.1K | SEC |
| 2023-03-24 | 03-28 | Lewis-Hall Freda C | Director | A 獲配股票 | 139K | – | – | 206K | SEC |
| 2023-03-24 | 03-28 | Wadhane Jitendra | Chief Accounting Officer | A 獲配股票 | 45.0K | – | – | 88.6K | SEC |
| 2023-03-24 | 03-28 | Feingold Jay | Chief Medical Officer | A 獲配股票 | 210K | – | – | 730K | SEC |
| 2023-03-24 | 03-28 | Yanchik Connealy Pamela | CFO and COO | A 獲配股票 | 210K | – | – | 594K | SEC |
| 2023-03-24 | 03-28 | Sullivan Lara | President and CEO | A 獲配股票 | 703K | – | – | 2.2M | SEC |
| 2023-03-17 | 03-23 | PFIZER INC | TenPercentOwner | P 公開市場買進 | 1.8M | 2.76 | 5.0M | 6.0M | SEC |
| 2023-03-17 | 03-23 | Pfizer Ventures (US) LLC | TenPercentOwner | P 公開市場買進 | 1.8M | 2.76 | 5.0M | 6.0M | SEC |
| 2023-03-17 | 03-21 | PFIZER INC | TenPercentOwner | P 公開市場買進 | 1.8M | 2.76 | 5.0M | 6.0M | SEC |
| 2023-03-17 | 03-21 | Pfizer Ventures (US) LLC | TenPercentOwner | P 公開市場買進 | 1.8M | 2.76 | 5.0M | 6.0M | SEC |
| 2023-01-03 | 01-03 | Yanchik Connealy Pamela | Chief Financial Officer | A 獲配股票 | 43.5K | – | – | 385K | SEC |
| 2023-01-03 | 01-03 | Feingold Jay | Chief Medical Officer | A 獲配股票 | 53.9K | – | – | 521K | SEC |
| 2023-01-03 | 01-03 | Sullivan Lara | Chief Executive Officer | A 獲配股票 | 95.7K | – | – | 1.5M | SEC |
| 2022-04-21 | 04-25 | Chin Mark | Other | S 公開市場賣出 | 1.7M | 3.05 | 5.3M | 0 | SEC |
| 2022-04-14 | 04-15 | Sullivan Lara | Chief Executive Officer | A 獲配股票 | 315K | – | – | 1.4M | SEC |
| 2022-04-14 | 04-15 | Feingold Jay | Chief Medical Officer | A 獲配股票 | 116K | – | – | 467K | SEC |
| 2022-04-14 | 04-15 | Yanchik Connealy Pamela | Chief Financial Officer | A 獲配股票 | 93.5K | – | – | 341K | SEC |
| 2022-03-31 | 04-04 | Lewis-Hall Freda C | Director | A 獲配股票 | 66.8K | – | – | 66.8K | SEC |
| 2022-03-31 | 04-04 | Cline Darren S | Director | A 獲配股票 | 66.8K | – | – | 76.8K | SEC |
| 2022-03-31 | 04-04 | Yanchik Connealy Pamela | Chief Financial Officer | A 獲配股票 | 248K | – | – | 248K | SEC |
| 2022-03-31 | 04-04 | Chin Mark | Director | A 獲配股票 | 66.8K | – | – | 66.8K | SEC |
| 2022-03-31 | 04-04 | Feingold Jay | Chief Medical Officer | A 獲配股票 | 307K | – | – | 351K | SEC |
| 2022-03-31 | 04-04 | Civik Thomas | Director | A 獲配股票 | 66.8K | – | – | 66.8K | SEC |
| 2022-03-31 | 04-04 | FLAVIN JOHN L | Director | A 獲配股票 | 66.8K | – | – | 238K | SEC |
| 2022-03-31 | 04-04 | Sullivan Lara | Chief Executive Officer | A 獲配股票 | 743K | – | – | 1.0M | SEC |
| 2021-12-08 | 12-09 | Cline Darren S | Director | P 公開市場買進 | 10.0K | 9.39 | 94K | 10.0K | SEC |
| 2021-11-18 | 11-19 | Civik Thomas | Director | P 公開市場買進 | 15.7K | 12.74 | 200K | 15.7K | SEC |
| 2021-10-13 | 10-15 | FLAVIN JOHN L | Director | C 轉換 | 2.4K | – | – | 172K | SEC |
| 2021-10-13 | 10-15 | Chin Mark | Director | C 轉換 | 1.4M | – | – | 1.4M | SEC |
| 2021-10-13 | 10-15 | Chin Mark | Director | P 公開市場買進 | 313K | 16.00 | 5.0M | 1.7M | SEC |
| 2021-10-13 | 10-15 | Cormorant Asset Management, LP | Other | C 轉換 | 669K | – | – | 669K | SEC |
| 2021-10-13 | 10-15 | Cormorant Asset Management, LP | Other | P 公開市場買進 | 450K | 16.00 | 7.2M | 1.1M | SEC |
| 2021-10-13 | 10-15 | Chen Bihua | DirectorOther | C 轉換 | 669K | – | – | 669K | SEC |
| 2021-10-13 | 10-15 | Chen Bihua | DirectorOther | P 公開市場買進 | 450K | 16.00 | 7.2M | 1.1M | SEC |
| 2021-10-13 | 10-15 | Cormorant Global Healthcare Master Fund, LP | Other | C 轉換 | 669K | – | – | 669K | SEC |
| 2021-10-13 | 10-15 | Cormorant Global Healthcare Master Fund, LP | Other | P 公開市場買進 | 450K | 16.00 | 7.2M | 1.1M | SEC |
| 2021-10-13 | 10-15 | Cormorant Private Healthcare Fund III LP | Other | C 轉換 | 669K | – | – | 669K | SEC |
| 2021-10-13 | 10-15 | Cormorant Private Healthcare Fund III LP | Other | P 公開市場買進 | 450K | 16.00 | 7.2M | 1.1M | SEC |
| 2021-10-13 | 10-15 | BAYER AKTIENGESELLSCHAFT | Other | C 轉換 | 2.7M | – | – | 2.7M | SEC |
| 2021-10-13 | 10-15 | Bayer World Investments B.V. | Other | C 轉換 | 2.7M | – | – | 2.7M | SEC |
| 2021-10-07 | 10-12 | Feingold Jay | Chief Medical Officer | A 獲配股票 | 43.8K | – | – | 43.8K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| GordonMD Global Investments LP | 10.0M | 30.2M | 新進 | 新進 |
| Pfizer Inc | 7.0M | 19.5M | 新進 | 新進 |
| Laurion Capital Management LP | 4.9M | 14.8M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | 6.2M | 新進 | 新進 |
| Atle Fund Management AB | 966K | 2.9M | 新進 | 新進 |
| BlackRock, Inc. | 868K | 2.6M | 新進 | 新進 |
| Palo Alto Investors LP | 864K | 2.6M | 新進 | 新進 |
| MARSHALL WACE, LLP | 831K | 2.5M | 新進 | 新進 |
| 文藝復興 RENAISSANCE TECHNOLOGIES LLC | 772K | 2.3M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 592K | 1.8M | 新進 | 新進 |
| Woodline Partners LP | 524K | 1.6M | 新進 | 新進 |
| 683 Capital Management, LLC | 459K | 1.4M | 新進 | 新進 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 429K | 1.3M | 新進 | 新進 |
| Longaeva Partners L.P. | 354K | 1.1M | 新進 | 新進 |
| Decheng Capital LLC | 327K | 984K | 新進 | 新進 |
| VANGUARD FIDUCIARY TRUST CO | 303K | 912K | 新進 | 新進 |
| JANE STREET GROUP, LLC | 290K | 873K | 新進 | 新進 |
| STATE STREET CORP | 249K | 749K | 新進 | 新進 |
| 千禧 MILLENNIUM MANAGEMENT LLC | 233K | 701K | 新進 | 新進 |
| UBS Group AG | 155K | 467K | 新進 | 新進 |
| Bank of New York Mellon Corp | 134K | 403K | 新進 | 新進 |
| NORTHERN TRUST CORP | 124K | 373K | 新進 | 新進 |
| NewEdge Wealth, LLC | 116K | 349K | 新進 | 新進 |
| XTX Topco Ltd | 111K | 334K | 新進 | 新進 |
| Two Sigma TWO SIGMA INVESTMENTS, LP | 84.0K | 253K | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 76 -2 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 76 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 34.2M · 40.9% |
| 合計季末市值 | 101M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 4.0M |
|---|---|
| 與上期比 | -10.3% |
| 佔流通股數 | 4.76% |
| 日均成交量 | 570K |
| 回補天數 | 7.0 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 4.0M | -10.3% | 4.76% | 570K | 7.0 |
| 2026-08-14 | 4.4M | +6.1% | 5.31% | 2.2M | 2.0 |
| 2026-07-31 | 4.2M | +28.2% | 5.00% | 997K | 4.2 |
| 2026-07-15 | 3.3M | +42.1% | 3.90% | 1.0M | 3.1 |
| 2026-06-30 | 2.3M | +13.6% | 2.75% | 1.8M | 1.3 |
| 2026-06-15 | 2.0M | +15.7% | 2.42% | 415K | 4.9 |
| 2026-05-29 | 1.7M | -3.8% | 2.09% | 608K | 2.9 |
| 2026-05-15 | 1.8M | -8.9% | 2.17% | 856K | 2.1 |
| 2026-04-30 | 2.0M | -12.5% | 2.38% | 361K | 5.5 |
| 2026-04-15 | 2.3M | -14.7% | 2.72% | 403K | 5.6 |
| 2026-03-31 | 2.7M | +6.8% | 3.19% | 361K | 7.4 |
| 2026-03-13 | 2.5M | -1.4% | 2.99% | 323K | 7.7 |
| 2026-02-27 | 2.5M | +3.4% | 3.03% | 256K | 9.9 |
| 2026-02-13 | 2.4M | +2.4% | 2.93% | 646K | 3.8 |
| 2026-01-30 | 2.4M | +3.4% | 2.86% | 606K | 3.9 |
| 2026-01-15 | 2.3M | +33.1% | 2.77% | 1.9M | 1.2 |
| 2025-12-31 | 1.7M | -10.3% | 2.08% | 2.9M | 1.0 |
| 2025-12-15 | 1.9M | -57.3% | 2.32% | 645K | 3.0 |
| 2025-11-28 | 4.5M | -0.4% | 5.42% | 591K | 7.7 |
| 2025-11-14 | 4.5M | +4.1% | 5.44% | 948K | 4.8 |
| 2025-10-31 | 4.4M | +2.6% | 5.23% | 560K | 7.8 |
| 2025-10-15 | 4.3M | +2.9% | 5.10% | 1.1M | 3.9 |
| 2025-09-30 | 4.1M | -5.2% | 4.95% | 687K | 6.0 |
| 2025-09-15 | 4.4M | +0.6% | 5.23% | 1.0M | 4.2 |
| 2025-08-29 | 4.3M | -13.9% | 5.20% | 570K | 7.6 |
| 2025-08-15 | 5.0M | +7.2% | 6.03% | 333K | 15.1 |